logo

For the Inventor, By the Inventor

Tokyo, Japan

Akio Odawara

This inventor holds 8 USPTO granted patents. Top assignee: Tanabe Seiyaku Company, Limited. Active years: 1990-1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akio Odawara. Retrieved from https://idiyas.com/inventor/akio-odawara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 18(Granted Patents)


Company Filing History:

goldMedal8 out of 324 
 
Tanabe Seiyaku Company, Limited
 patents

Years Active: 1990-1995

Loading Chart...
8 patents (USPTO):Explore Patents
1. 5387581 - Pharmaceutical composition of aspirin and a benzothiazepine for (1995-02-07),
2. 5382577 - Pharmaceutical composition for inhibiting platelet aggregation (1995-01-17),
3. 5206428 - Tetrahydronaphthalene derivatives and preparation thereof (1993-04-27),
4. 5206418 - Amino-tetrahydronaphthalene derivatives (1993-04-27),
5. 5190975 - Indan derivatives used for treating thromboses or asthma (1993-03-02),
6. 5030652 - Indan derivatives and pharmaceutical preparation thereof (1991-07-09),
7. 4975460 - Indanoxyacetic acid derivatives (1990-12-04),
8. 4963587 - Glycine derivative and pharmaceutical preparation thereof (1990-10-16),

Title: Akio Odawara: Innovator in Pharmaceutical Composition

Introduction

Akio Odawara is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that inhibit platelet aggregation. With a total of 8 patents to his name, Odawara's work has had a notable impact on medical science.

Latest Patents

Among his latest patents, Odawara has developed a pharmaceutical composition that combines acetylsalicylic acid, commonly known as aspirin, with a benzothiazepine derivative. This innovative composition is designed to inhibit platelet aggregation, which is crucial in preventing blood clots. Another significant patent involves a composition that includes 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine, also aimed at inhibiting platelet aggregation. These advancements showcase his dedication to improving therapeutic options in the medical field.

Career Highlights

Odawara is currently associated with Tanabe Seiyaku Company, Limited, where he continues to push the boundaries of pharmaceutical research. His work has not only contributed to the company's portfolio but has also advanced the understanding of drug interactions and efficacy in treating various conditions.

Collaborations

Throughout his career, Odawara has collaborated with notable colleagues, including Yasuhiko Sasaki and Harumichi Kohno. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Akio Odawara stands out as a key figure in the pharmaceutical industry, with his innovative patents and collaborative spirit. His contributions are paving the way for future advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…